Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.08%
SPX
-0.29%
IXIC
-0.40%
FTSE
+0.01%
N225
+0.77%
AXJO
+0.23%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks

OMER is now undervalued and could go up 285%

Sep 28, 2024, 12:00 PM
6.89%
What does OMER do
Omeros, a Seattle-based biopharmaceutical company with 198 employees, focuses on developing therapeutics for immunologic disorders and is advancing several candidates, including narsoplimab and OMS527, in clinical trials. The company went public on October 8, 2009.
Based on our analysis, Omeros Corporation has received an undervalued rating of 4 out of 5 stars from Cashu. The company exhibits several key financial ratios that suggest it is trading below its intrinsic value compared to its sector peers. Firstly, Omeros has a Price-to-Book (PB) ratio of 1.65, significantly lower than the sector average of 2.71. A lower PB ratio can indicate that a stock is undervalued relative to its assets, which may present a buying opportunity for investors. In terms of profitability, Omeros reports a Net Profit Margin of -187.13, compared to the sector's -138.46. While both figures are negative, Omeros' margin is worse, signaling operational challenges. However, this may also reflect investments in future growth that could lead to improved margins over time. The company's Return on Equity (ROE) stands at an impressive 55.34, vastly outperforming the sector average of -74.04. A high ROE indicates that Omeros is generating significant returns on shareholders' equity, suggesting efficient management and potential for strong future performance. Lastly, Omeros' Return on Assets (ROA) ratio of -31.15, although negative, is better than the sector's -47.67. This indicates that Omeros is using its assets more effectively than many of its competitors, even amidst overall challenges. These ratios collectively illustrate that Omeros has the potential for future growth and recovery, making it an attractive investment opportunity despite current challenges. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care

More Signals

Feature in Progress
This section is under development. Check back soon for updates!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.